Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1993-01-21
1994-11-15
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514565, 514616, 514621, 514913, 560 34, A01N 3712, A01N 3744
Patent
active
053648846
ABSTRACT:
The invention relates to arginine and arginine-like compounds and to methods employing these compounds as ocular hypotensive agents. These compounds are effective when applied topically, may be used in low concentrations and are nontoxic. Additionally, the invention includes several new arginine derivatives with varying lipophilicities particularly suited for topical administration.
REFERENCES:
patent: 4515800 (1985-05-01), Cavero et al.
patent: 4694022 (1987-09-01), Gerson et al.
patent: 4722933 (1993-02-01), Horn
patent: 4822819 (1989-04-01), De Santis et al.
patent: 4822820 (1989-04-01), De Santis et al.
patent: 4828869 (1989-05-01), Muchowski
patent: 5182102 (1993-01-01), De Santis, Jr. et al.
patent: 5182258 (1983-01-01), Chiou
patent: 5208256 (1993-05-01), Ueno
patent: 5217997 (1983-06-01), Levere et al.
Andronik-Lion et al., "Formation of Nitric Oxide by Cytochrome P450-Catalyzed Oxidation of Aromatic Amidoximes," Biochem. Biophys. Res. Commun., 185(1):452-458, 1992.
Bodor and Visor, "Formation of Adrenaline in the Iris-Ciliary Body from Adrenalone Diesters," Exp. Eye. Res., 38:621-626, 1984.
Bredt and Snyder, "Isolation of Nitric Oxide Synthetase, A Calmodulin-Requiring Enzyme," Proc. Natl. Acad. Sci. USA, 87:682-685, 1990.
Bundgaard, "Design and Application of Prodrugs," In: "A textbook of Drug Design and Development," P. Krogsguard-Larsen and H. Bundgaard, Eds., Harvard Academic Publishers, Philadelphia, PA 1911, pp. 124-127; 152-159.
Chiou and Li, "Ocular Hypotensive Actions of Serotonin Antagonist-Ketanserin Analogs," J. Ophthalmol., 8(1):11-21, 1992.
Dhaon et al., "Esterification of N-Protected .alpha.-Amino Acids with Alcohol/Carbodiimide/4-(Dimethylamino)-pyridine. Racemization of Aspartic and Blutamic Acid Derivatives," J. Org. Chem., 47:1962-1965, 1982.
Feelisch et al., "Thio;-Mediated Generation of Nitric Oxide Accounts for the Vasodilator Action of Furoxans," Biochem. Pharmacol., 44(6):1149-1157, 1992.
Feelisch, "The Biochemical Pathways of Nitric Oxide Formation from Nitrovasodilators: Appropriate Choice of Exogenous No Donors and Aspects of Preparation and Handling of Aqueous No Solutions," J. Cardiovasc. Pharmacol., 17(Suppl. 3):S25-S32, 1991.
Gibson et al., "An Investigation of Some S-Nitrosothiols, and of Hydroxy-Arginine, on the Mouse Anococcygeus," Br. J. Pharmacol., 107:715-721, 1992.
Greco et al., "GH Secretion in Open-Angle Glaucoma," Ophthalmologica, Basel, 179:168-172, 1979.
Hannappel et al., "Amino Acid Pattern in Human Aqueous Humor of Patients with Senile Cataract and Primary Open-Angle Glaucoma," Ophthalmic Res., 17:341-343, 1985.
Horio and Murad, "Solubilization of Guanylyl Cyclase from Bovine Rod Outer Segments and Effects of Lowering Ca.sup.2+ and Nitro Compounds," J. Biol. Chem., 266(6):3411-3415, 1991.
Kilbourne et al., "Arginine Antagonists for Inhibition of Systemic Hypotension Associated with Nitric Oxide Production or Endothelialderived Relaxing Factor," Chem. Abstracts, CA Selects: Antitumor Agents, 26:15, Abstract #115:248105v, 1991, regarding PCT application WO 9109524.
Lee, "Mechanisms and Facilitation of Corneal Drug Penetration," J. Controlled Release, 11:79-90, 1990.
Lee and Li, "Prodrugs for Improved Ocular Drug Delivery," Advanced Drug Delivery Reviews, 3:1-38, 1989.
Ludwig and Van Ooteghem, "The Evaluation of Viscous Ophthalmic Vehicles by Slit Lamp Fluorophotometry in Humans," Int. J. Pharm., 54:95-102, 1989.
Moncada et al., "Nitric Oxide: Physiology, Pathophysiology, and Pharmacology," Pharmacol. Rev., 43(2):109-142, 1991.
Myers, "Vasorelaxant Properties of the Endothelium-Derived Relaxing Factor More Closely Resemble S-Nitrosocysteine than Nitric Oxide," Nature, 345:161-162, 1990.
Nathanson, "Nitrovasodilators as a New Class of Ocular Hypotensive Agents," J. Pharmacol. Exp. Ther., 260(30:956-964, 1992.
Park, "Reaction of S-Nitrosoglutathione with Sulhydryl Groups in Protein," Biochem. Biophys. Res. Commun., 152(2):916-920, 1988.
Patel and Price, "Synthesis of Benzyl Esters of .alpha.-Amino Acids," J. Org. Chem., 30:3575-3576, 1965.
Radomski et al., "S-Nitroso-Glutathione Inhibits Platelet Activation in Vitro and in Vivo, " Br. J. Pharmacol., 107:745-749, 1992.
Robin et al., "Effects of ALO 2145 on Intraocular Pressure Following Argon Laser Trabeculoplastry," Arch. Ophthalmol., 105:646-650, 1987.
Robin et al., "Effects of Topical ALO 2145 (.rho.-Aminoclonidine Hydrochloride) on the Acute Intracular Pressure After Argon Laser Iridotomy," Arch. Ophthalmol., 105:1208-1211, 1987.
Rubanyl et al., "Evidence That a S-Nitrosothiol, but Not Nitric Oxide, May Be Identical with Endothelium-Derived Relaxing Factor," J. Cardiovasc. Pharmacol., 17(Suppl. 3):S41-S45, 1991.
Thomas and Ramwell, "Interaction of Non-Arginine Compounds with the Endothelium Derived Relaxing Factor Inhibitor, N.sup.G -Monomethyl L-Arginine," J. Pharmacol. Exp. Ther., 260(2):676-679, 1992.
Traylor and Sharma, "Why No?", Biochemistry, 31(11):2647-2648, 1992.
Venturini et al., "Synthesis of Nitric Oxide in the Bovine Retina," Biochem. Biophys. Res. Commun., 180(2):920-925, 1991.
Yoshimura et al., "The Use of Arginine of Ornithine as an Immunostimulator," Chem. Abstracts, CA Selects:Antitumor Agents, 26:15, Abstract #115:248101r, 1991, regarding PCT application WO 9109524.
Zervas et al., "Studies on Arginine Peptides. I. Intermediates in the Synthesis of N-Terminal and C-Terminal Arginine Peptides," J. Org. Chem., 22:1515-1521, 1957.
Dialog Search Report.
Chiou George C. Y.
Varma Rajender S.
Baylor College of Medicine
Conrad Joseph M.
Dees Jos,e G.
LandOfFree
Arginine compounds as ocular hypotensive agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arginine compounds as ocular hypotensive agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arginine compounds as ocular hypotensive agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1098099